GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (AHS Cancer Control Alberta)

N/A

Report date: 2026/05/02 20:00:18

Base Information

Drug NameGPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (AHS Cancer Control Alberta)
Drug Alias NameGCAR1
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionTransmembrane glycoprotein NMB modulatorsT lymphocyte replacements
TargetsTransmembrane glycoprotein NMB
Therapy Area/IndicationsTriple Negative Breast NeoplasmsCarcinoma, Renal CellSarcoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAHS Cancer Control Alberta
China Registration ClassN/A

Develop Information

Active CompaniesCanadian Institutes Of Health Research (Cihr)University Of CalgaryCanadian Cancer Trials Group +[4] 
Inactive CompaniesN/A
Active IndicationsTriple Negative Breast NeoplasmsCarcinoma, Renal CellSarcoma +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A